Replimune Group Inc REPL

Healthcare Biotechnology

Replimune Group, Inc. a clinical-stage biotechnology company engaged in the development of a novel class of oncolytic immunotherapies. The Company’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. RP1 (vusolimogene oderparepvec) is its lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response. It is also developing additional product candidates, RP2 and RP3, to enhance anti-tumor immune responses and are intended to address additional tumor types, including traditionally less immune responsive tumor types. RP2 additionally expresses an anti-CTLA-4 antibody-like molecule, as well as GALV-GP R- and GM-CSF.

NDAQ:REPL - Post by User

Replimune Group Inc

<< Previous

Bullboard Posts

Next >>

Post by BullishEdge56on Nov 22, 2024 2:10pm

20 Views

Post# 36326450

REPL : FDA Fast Track Sparks Price Target Upgrades

$REPL just scored 3 analyst upgrades, with new price targets bumped to $17-18. This is the kind of boost you see when the FDA puts you on the fast track for approval. Also keeping an eye on MYNZ—it’s gaining attention as a stock with strong breakout potential.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec